Buy & Sell State Street Technology Select Sector SPDR ETF (XLK) – State Street Technology Select Sector SPDR ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Sector/ThematicSector
- -10.85%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 18 daysTypical Hold Time
Over the past 52 weeks, State Street Technology Select Sector SPDR ETF has traded between a low of $113.41 and a high of $179.48, highlighting its annual price range. Over the past three months, State Street Technology Select Sector SPDR ETF has recorded a drawdown of -10.85%, reflecting recent price volatility. On average, investors hold State Street Technology Select Sector SPDR ETF for approximately 18 days, indicating typical investor behavior on the platform.
About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Most Recent News
BC launches Outdoor Sector Coalition to boost economy, health, and conservation of its outdoors.
A coalition of over 2,000 organizations in British Columbia has formed to support the province's outdoor sector, which is a $17 billion industry employing 80,000 people. The coalition aims to enhance health benefits, support outdoor businesses, and p...

Nvidia's Q1 2027 earnings face high expectations amid strong past beats but mixed stock reactions.
Nvidia is set to report its Q1 2027 earnings with Wall Street expecting $78.8 billion in revenue and $1.77 EPS, marking record growth. Historically, Nvidia has consistently beaten revenue and EPS estimates, but recent earnings have shown that the sto...

ESR1-mutated metastatic breast cancer market to grow 9.6% CAGR with new oral SERDs and targeted therapies.
The ESR1-mutated metastatic breast cancer market is projected to grow rapidly at a 9.6% CAGR from 2026 to 2036, driven by rising cases of endocrine-resistant HR-positive/HER2-negative breast cancer and advances in precision oncology. Novel therapies ...
